Work

Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp

Year: 2022

Type: article

Abstract: Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited. Ibrexafungerp is a novel antifungal agent which was approved in 2021 for treatment of vulvovaginal candidiasis. We present a case of recurrent vulvovaginal candidiasis successfully treated with ibrexafungerp.

Source: Journal of Investigative Medicine High Impact Case Reports

DOI: 10.1177/23247096221123144

Authors: Leah M. Grant, Robert Orenstein

Institution: Mayo Clinic Hospital

Language: English

Topic: Antifungal resistance and susceptibility

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $750